SCHEDULE: Armistice Capital Discloses 6.93% Stake in Rigel Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,280,000 shares, representing 6.93% of Rigel Pharmaceuticals, Inc. common stock.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, indicating their beneficial ownership of 1,280,000 shares of Rigel Pharmaceuticals, Inc. common stock.
• This holding represents 6.93% of the total class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an existing ownership stake rather than new strategic developments or financial performance.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund pursuant to an Investment Management Agreement and thus may be deemed to beneficially own the securities.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes, suggesting Armistice Capital and Steven Boyd are not seeking to control Rigel Pharmaceuticals but rather hold a significant minority position.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Armistice Capital may influence market perception and trading activity.
• Management: The filing indicates a substantial investor's interest, which may lead to increased scrutiny or engagement with management.

Key Dates

Keywords

Schedule 13G, Rigel Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, Investment Management